PT3054977T - Diagnóstico e tratamento da síndrome do intestino irritável e da doença inflamatória intestinal - Google Patents

Diagnóstico e tratamento da síndrome do intestino irritável e da doença inflamatória intestinal

Info

Publication number
PT3054977T
PT3054977T PT14851688T PT14851688T PT3054977T PT 3054977 T PT3054977 T PT 3054977T PT 14851688 T PT14851688 T PT 14851688T PT 14851688 T PT14851688 T PT 14851688T PT 3054977 T PT3054977 T PT 3054977T
Authority
PT
Portugal
Prior art keywords
diagnosis
treatment
inflammatory bowel
bowel disease
bowel syndrome
Prior art date
Application number
PT14851688T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Cedars Sinai Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52813648&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3054977(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cedars Sinai Medical Center filed Critical Cedars Sinai Medical Center
Publication of PT3054977T publication Critical patent/PT3054977T/pt

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483Physical analysis of biological material
    • G01N33/487Physical analysis of biological material of liquid biological material
    • G01N33/49Blood
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854Immunoglobulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/205Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/06Gastro-intestinal diseases
    • G01N2800/065Bowel diseases, e.g. Crohn, ulcerative colitis, IBS

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Ecology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
PT14851688T 2013-10-09 2014-10-09 Diagnóstico e tratamento da síndrome do intestino irritável e da doença inflamatória intestinal PT3054977T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361888658P 2013-10-09 2013-10-09

Publications (1)

Publication Number Publication Date
PT3054977T true PT3054977T (pt) 2021-10-14

Family

ID=52813648

Family Applications (1)

Application Number Title Priority Date Filing Date
PT14851688T PT3054977T (pt) 2013-10-09 2014-10-09 Diagnóstico e tratamento da síndrome do intestino irritável e da doença inflamatória intestinal

Country Status (19)

Country Link
US (2) US9851361B2 (OSRAM)
EP (1) EP3054977B1 (OSRAM)
JP (1) JP6567509B2 (OSRAM)
KR (1) KR102259588B1 (OSRAM)
CN (1) CN105744956B (OSRAM)
AU (2) AU2014331841B2 (OSRAM)
BR (1) BR112016007474A2 (OSRAM)
CA (1) CA2923651C (OSRAM)
CL (1) CL2016000820A1 (OSRAM)
ES (1) ES2892905T3 (OSRAM)
IL (1) IL244971B2 (OSRAM)
MX (1) MX383423B (OSRAM)
NZ (1) NZ717633A (OSRAM)
PE (1) PE20160882A1 (OSRAM)
PL (1) PL3054977T3 (OSRAM)
PT (1) PT3054977T (OSRAM)
RU (1) RU2683781C2 (OSRAM)
SG (1) SG11201601733VA (OSRAM)
WO (1) WO2015054529A1 (OSRAM)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010213708B2 (en) 2009-02-11 2015-12-10 Cedars-Sinai Medical Center Antibody to cytolethal distending toxin of Campylobacter jejuni
US11693009B2 (en) 2009-02-11 2023-07-04 Cedars-Sinai Medical Center Methods for detecting post-infectious irritable bowel syndrome
AU2013315981B2 (en) 2012-09-17 2019-04-18 Cedars-Sinai Medical Center Diagnosis and treatment of motility disorders of the gut and bladder, and of fibromyalgia
PE20160882A1 (es) 2013-10-09 2016-09-14 Cedars Sinai Medical Center Diagnostico y tratamiento del sindrome del intestino irritable y la enfermedad inflamatoria intestinal
KR102426541B1 (ko) 2014-10-09 2022-07-29 세다르스-신나이 메디칼 센터 과민성 장 증후군을, 염증성 장 질환 및 셀리악 병과 구별하기 위한 방법 및 시스템
CN106053827A (zh) * 2016-05-17 2016-10-26 上海凯璟生物科技有限公司 一种肠易激综合症标志物Vinculin抗体检测试剂盒及其制备方法
CN105784989A (zh) * 2016-05-17 2016-07-20 上海凯璟生物科技有限公司 一种肠易激综合症标志物CdtB抗体检测试剂盒及其制备方法
JP7475811B2 (ja) * 2016-05-20 2024-04-30 シーダーズ―シナイ メディカル センター 遺伝子に基づく炎症性腸疾患の診断
KR20190111094A (ko) 2017-01-30 2019-10-01 세다르스-신나이 메디칼 센터 경피증의 진단
RU2763258C1 (ru) * 2020-07-13 2021-12-28 Евгения Николаевна Воронина Способ дифференциальной диагностики воспалительных заболеваний кишечника у детей по комплексу клинико-анамнестических, лабораторных и инструментальных критериев

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5691151A (en) * 1994-10-07 1997-11-25 Regents Of University Of California Methods of screening for ulcerative colitis and crohn's disease by detecting VH3-15 autoantibody and panca
US6562629B1 (en) 1999-08-11 2003-05-13 Cedars-Sinai Medical Center Method of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth by detecting the presence of anti-saccharomyces cerivisiae antibodies (asca) in human serum
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
FR2806805A1 (fr) 2000-03-22 2001-09-28 Centre Nat Rech Scient SEQUENCE PEPTIDIQUES COMPRENANT UN OU PLUSIEURS MOTIFS DE LIAISON AUX PROTEINES DE LA FAMILLE Ena/VASP, ET LEURS UTILISATIONS
WO2003097854A2 (en) 2002-05-17 2003-11-27 Sugen, Inc. Novel biomarkers of tyrosine kinase inhibitor exposure and activity in mammals
EP2444409A2 (en) 2002-09-16 2012-04-25 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US7595386B2 (en) 2003-01-24 2009-09-29 William Beaumont Hospital Methods and compositions for heat activated gene therapy using cytolethal distending toxin
CA2521369A1 (en) * 2003-04-08 2004-10-28 Progenics Pharmaceuticals, Inc. The use of peripheral opiois antagonists, especially methylnaltrexone to treat irritable bowel syndrome
EP2280285A1 (en) * 2003-09-15 2011-02-02 Oklahoma Medical Research Foundation Method of using cytokine assays to diagnose, treat, and evaluate inflammatory and autoimmune diseases
PT1698698E (pt) 2003-12-05 2014-03-06 Fuso Pharmaceutical Ind Genes da toxina distensora citoletal como alvos para a deteção de bactérias campylobacter
US8148067B2 (en) 2006-11-09 2012-04-03 Xdx, Inc. Methods for diagnosing and monitoring the status of systemic lupus erythematosus
PL2223121T3 (pl) 2007-12-20 2012-12-31 Index Diagnostics Ab Publ Sposób różnicowania NZJ i ZJD oraz dalsze rozróżnienie odmian NZJ
ES2529060T3 (es) 2008-11-24 2015-02-16 Cedars-Sinai Medical Center Derivados antioxidantes de la camptotecina y nanoesferas antineoplásicas antioxidantes de los mismos
WO2010093776A1 (en) 2009-02-11 2010-08-19 Cedars-Sinai Medical Center Antibiotic therapy to reduce the likelihood of developing post-infectious irritable bowel syndrome
AU2010213708B2 (en) 2009-02-11 2015-12-10 Cedars-Sinai Medical Center Antibody to cytolethal distending toxin of Campylobacter jejuni
FR2942541A1 (fr) 2009-02-25 2010-08-27 Assist Publ Hopitaux De Paris Procede de diagnostic d'une vascularite
RU2397178C1 (ru) * 2009-02-27 2010-08-20 Федеральное государственное учреждение науки "Центральный научно-исследовательский институт эпидемиологии" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека Диагностическая тест-система в формате иммуночипа и способ серологической дифференциальной диагностики сифилиса
IT1400989B1 (it) 2010-07-13 2013-07-05 Segix Italia S R L Ora Istituto Biochimico Naz Savio S R L Forme di somministrazione orale a rilascio controllato di rifampicina per il trattamento di infezioni batteriche dell' apparato intestinale.
GB201017520D0 (en) 2010-10-15 2010-12-01 Sense Proteomic Ltd Biomarkers
AU2013315981B2 (en) * 2012-09-17 2019-04-18 Cedars-Sinai Medical Center Diagnosis and treatment of motility disorders of the gut and bladder, and of fibromyalgia
PE20160882A1 (es) 2013-10-09 2016-09-14 Cedars Sinai Medical Center Diagnostico y tratamiento del sindrome del intestino irritable y la enfermedad inflamatoria intestinal
KR102426541B1 (ko) 2014-10-09 2022-07-29 세다르스-신나이 메디칼 센터 과민성 장 증후군을, 염증성 장 질환 및 셀리악 병과 구별하기 위한 방법 및 시스템
CN106091069A (zh) 2016-06-15 2016-11-09 安徽省绿巨人环境技术有限公司 一种废水再利用装置
KR20190111094A (ko) 2017-01-30 2019-10-01 세다르스-신나이 메디칼 센터 경피증의 진단

Also Published As

Publication number Publication date
EP3054977A1 (en) 2016-08-17
PE20160882A1 (es) 2016-09-14
CN105744956A (zh) 2016-07-06
KR20160062161A (ko) 2016-06-01
RU2016116766A (ru) 2017-11-15
AU2020203468A1 (en) 2020-06-18
ES2892905T3 (es) 2022-02-07
US20170038393A1 (en) 2017-02-09
MX2016004167A (es) 2016-06-24
US9851361B2 (en) 2017-12-26
RU2683781C2 (ru) 2019-04-02
MX383423B (es) 2025-03-14
CL2016000820A1 (es) 2016-09-23
IL244971B1 (en) 2023-08-01
NZ717633A (en) 2021-07-30
WO2015054529A1 (en) 2015-04-16
EP3054977A4 (en) 2017-04-12
CA2923651A1 (en) 2015-04-16
KR102259588B1 (ko) 2021-06-02
AU2014331841A1 (en) 2016-03-24
PL3054977T3 (pl) 2021-12-20
AU2014331841B2 (en) 2020-03-12
EP3054977B1 (en) 2021-07-21
CN105744956B (zh) 2021-07-20
JP2017502253A (ja) 2017-01-19
US10352944B2 (en) 2019-07-16
IL244971B2 (en) 2023-12-01
US20180196063A1 (en) 2018-07-12
BR112016007474A2 (pt) 2017-09-12
CA2923651C (en) 2023-03-14
HK1221898A1 (zh) 2017-06-16
SG11201601733VA (en) 2016-04-28
JP6567509B2 (ja) 2019-08-28
IL244971A0 (en) 2016-05-31

Similar Documents

Publication Publication Date Title
SG11201601733VA (en) Diagnosis and treatment of irritable bowel syndrome and inflammatory bowel disease
EP2968397A4 (en) DIAGNOSIS AND TREATMENT OF FIBROSIS
HUE049569T2 (hu) Immunrendszerrel kapcsolatos és gyulladásos megbetegedések kezelése
IL244089A0 (en) Diagnostic methods and preparations for the treatment of glioblastoma
EP2958936A4 (en) METHOD AND COMPOSITIONS FOR TREATING CORI DISEASE
EP2971127A4 (en) METHOD FOR DIAGNOSIS AND TREATMENT OF INFLAMMABLE ENDURANCE
EP2968208A4 (en) TREATMENT OF CATAPLEXIA
IL275368B (en) Diagnosis and treatment of autoimmune diseases
EP2997162A4 (en) Methods for diagnosing and treating inflammatory bowel disease
PT3626270T (pt) Tratamento de doenças cardiovasculares
ZA201408059B (en) Compositions and methods for the treatment of inflammatory bowel disease
ZA201507718B (en) The local treatment of inflammatory ophthalmic diseases
EP3046629A4 (en) Treatment of inflammatory skin disease
LT3021873T (lt) Kompozicija, skirta uždegiminių sąnarių ligų gydymui
IL242516B (en) Treatment of pulmonary and other conditions
HUE042691T2 (hu) Tiazolo-pirimidinon felhasználása gyulladásos bélbetegségek kezeléséhez
EP3016968A4 (en) Diagnosis and treatment of autoimmune diseases
EP2994486A4 (en) USE OF ANTI-EOTAXINE ANTIBODIES FOR THE TREATMENT OF CHRONICALLY INFLAMMABLE ENDURANCE
PL2870968T3 (pl) Leczenie klinoptilolitem zapalnych chorób jelit
GB201318088D0 (en) Oligonucleotide probe set and methods for the diagnosis of irritable bowel syndrome and inflammatory bowel disease
SG11201506509TA (en) Use of pidotimod to treat inflammatory bowel disease
GB201320014D0 (en) Treatment of cardiovascular disease
IL241785A0 (en) Using fidotimide to treat irritable bowel syndrome
GB201521918D0 (en) Antibodies for treatment and diagnosis of inflammatory bowel disease
GB201321628D0 (en) Treatment of disease